Atheronova Inc (AHRO) 0.1150 $AHRO
AtheroNova Receives Notice of Issuance of Its 3rd US Patent
PR Newswire - Fri Feb 13, 7:10AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.
AtheroNova concludes USD3m in public offering
M2 - Mon Nov 03, 3:39AM CST
Biotech company AtheroNova (Other OTC:AHRO) disclosed on Friday the completion of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.
AtheroNova Announces Closing of Public Offering of Common Stock and Warrants
PR Newswire - Fri Oct 31, 3:13PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the closing of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities were sold at a price to the public of $0.75 per share of common stock and $0.00001 per warrant. The warrants have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are approximately $3,000,050, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
AtheroNova Prices Public Offering of Common Stock and Warrants
PR Newswire - Tue Oct 28, 4:58PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant. The warrants will have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and will expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are expected to be $3,050,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. The offering is expected to close on or about October 31, 2014, subject to customary closing conditions. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
PR Newswire - Wed Jul 30, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. The Company will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b, at which time the topline data will be presented together in approximately six to eight months.
AtheroNova files pre-IND under Section 505(b)(2) process for its bile acids platform
M2 - Wed Jul 16, 8:44AM CDT
Biotechnology company AtheroNova (Other OTC :AHRO) said on Tuesday that it has filed pre-Investigational New Drug (pre-IND) documents using a patented bile acid in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone.
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2)
GlobeNewswire - Tue Jul 15, 7:22AM CDT
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that it has filed pre-Investigational New Drug (pre-IND) documents with the US Food and Drug Administration (the "FDA"
under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (the "Act" using a patented bile acid, in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone. The Company has received its initial pre-IND file number from the FDA indicating the initiation of the review process. Section 505(b)(2) of the Act specifically allows the FDA to rely on data not developed by the applicant company for approval of a New Drug Application ("NDA" for their intent to use previously approved active ingredient(s) in a combination product or for a new indication not previously approved.
AtheroNova Receives Notice of Issuance of Its 3rd US Patent
PR Newswire - Fri Feb 13, 7:10AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.
AtheroNova concludes USD3m in public offering
M2 - Mon Nov 03, 3:39AM CST
Biotech company AtheroNova (Other OTC:AHRO) disclosed on Friday the completion of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.
AtheroNova Announces Closing of Public Offering of Common Stock and Warrants
PR Newswire - Fri Oct 31, 3:13PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the closing of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities were sold at a price to the public of $0.75 per share of common stock and $0.00001 per warrant. The warrants have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are approximately $3,000,050, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
AtheroNova Prices Public Offering of Common Stock and Warrants
PR Newswire - Tue Oct 28, 4:58PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant. The warrants will have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and will expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are expected to be $3,050,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. The offering is expected to close on or about October 31, 2014, subject to customary closing conditions. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
PR Newswire - Wed Jul 30, 6:00AM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. The Company will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b, at which time the topline data will be presented together in approximately six to eight months.
AtheroNova files pre-IND under Section 505(b)(2) process for its bile acids platform
M2 - Wed Jul 16, 8:44AM CDT
Biotechnology company AtheroNova (Other OTC :AHRO) said on Tuesday that it has filed pre-Investigational New Drug (pre-IND) documents using a patented bile acid in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone.
AtheroNova Announces Pre-IND Filing Under Section 505(b)(2)
GlobeNewswire - Tue Jul 15, 7:22AM CDT
AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that it has filed pre-Investigational New Drug (pre-IND) documents with the US Food and Drug Administration (the "FDA"
under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (the "Act" using a patented bile acid, in combination with a statin for the treatment of patients who fail to reach their LDL cholesterol target with statin treatment alone. The Company has received its initial pre-IND file number from the FDA indicating the initiation of the review process. Section 505(b)(2) of the Act specifically allows the FDA to rely on data not developed by the applicant company for approval of a New Drug Application ("NDA" for their intent to use previously approved active ingredient(s) in a combination product or for a new indication not previously approved. 
